• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

byConstance Wu
December 9, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Rilonacept significantly lowered pericarditis recurrence risk compared to placebo.

2. Rilonacept rapidly resolved recurrent pericarditis episodes in at risk patients.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recurrent pericarditis is characterized by chronic and debilitating pericardial inflammation with limited treatment options such as glucocorticoids. However, the nonspecific immunosuppression property of glucocorticoids is particularly concerning for long-term use. Alternatively, interleukin-1 inhibition is a potential therapeutic for patients with systemic inflammation including pericarditis. As such, this study evaluated whether rilonacept, an interleukin-1α and interleukin-1β cytokine trap, could reduce the risk of pericarditis recurrence. The study determined rilonacept significantly lowered pericarditis recurrence risk, while rapidly resolving pericarditis episodes. The randomized control trial was limited by the randomized-withdrawal trial study design. Nonetheless, this study’s results are significant, and its findings highlight an effective treatment reduce recurrent pericarditis risk in patients with rilonacept treatment.

Click to read the study in NEJM

Relevant Reading: Effect of Anakinra on Recurrent Pericarditis Among Patients with Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial

RELATED REPORTS

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke

Long-term colchicine does not reduce recurrent events following ischemic stroke

In-Depth [randomized controlled trial]: This randomized-withdrawal trial enrolled 86 participants in a multicenter study in four countries. Participants included in the study were ≥ 12 years of age with recurrent pericarditis, presented with pericarditis during at least a second recurrence, and received combinatorial treatment of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids. Participants with a pain score of less than 4 on a numerical rating scale were excluded from this study. The participants were randomized in a 1:1 ratio to weekly receive rilonacept or placebo, respectively. The primary endpoint was recurrence events. A recurrence event was defined as return of pericarditis pain and an increased in C-reactive protein (CRP) levels. During the run-in period, the median time to pain response was 5 days (95% confidence interval [CI], 4 to 6) and the median time to CRP level normalization was 7 days (95% CI, 5 to 8). Out of the enrolled 86 participants, 61 participants completed the run-in period and underwent randomization. At the end of the randomized-withdrawal period, rilonacept led to a significantly lower pericarditis recurrence risk compared to the placebo (hazard ratio, 0.04; 95% CI, 0.01 to 0.18; P<0.001). During this period, 2 of 30 participants (7%) in the rilonacept group had a pericarditis recurrence compared to 23 of 31 patients (74%) in the control group. Additionally, 17 of 21 participants (81%) had a persistent clinical response at 16 weeks in the rilonacept group compared to 4 of 20 participants (20%) in the control group (difference, 61; 95% CI, 37 to 85; P<0.001). Furthermore, 17 of 21 participants (81%) presented with absent or minimal pericarditis symptoms in the rilonacept group compared to 5 of 20 participants (25%) in the control group (difference, 56; 95% CI, 31 to 81; P<0.001). Finally, injection-site reactions and upper respiratory tract infections were the most common adverse events. Overall, 29 participants (34%) and 7 participants (23%), all whom received rilonacept, had injection-site reactions and upper respiratory tract infections, respectively. Taken together, rilonacept significantly lowered the risk of pericarditis recurrence in at-risk patients.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: colchicineinterleukin-1 inhibitionpericarditisrilonacept
Previous Post

IV alteplase improves functional outcomes in patients with stroke of unknown onset

Next Post

Hyoscine butylbromide and acetaminophen have comparable effects for pediatric non-specific colicky abdominal pain

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

March 3, 2025
#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke
StudyGraphics

#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke

August 15, 2024
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Long-term colchicine does not reduce recurrent events following ischemic stroke

August 7, 2024
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Colchicine does not reduce risk of atrial fibrillation or myocardial injury after non-cardiac surgery

November 28, 2023
Next Post
Behavioral dysregulation in infancy predicts later child mental health

Hyoscine butylbromide and acetaminophen have comparable effects for pediatric non-specific colicky abdominal pain

1 in 5 US women report delayed contraceptive initiation after sexual debut

Improved contraception use with progestogen-only pill and rapid access vs emergency contraception

#VisualAbstract: Addition of indoximod to taxane chemotherapy does not improve survival in patients with metastatic breast cancer

#VisualAbstract: Addition of indoximod to taxane chemotherapy does not improve survival in patients with metastatic breast cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.